Will new injection devices for interferon beta-1a s.c. Affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East

International Journal of Neuroscience

Volumn 121, Issue 4, 2011, Pages 171-175

  Deleu, Dirk ^a   Alsharoqi, Issa ^b   Jumah, Mohammed Ali Al ^c   Tahan, Abdel Rahman Al ^d   Bohlega, Saeed ^e   Dahdaleh, Maurice ^f   Inshasi, Jihad ^g   Khalifa, Ahmad ^h   Szólics, Miklos ⁱ   Yamout, Bassem I ^j  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b Neurology Unit   (Bahrain)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^d KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^e KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^f Arab Medical Centre   (Jordan)

^g RASHID HOSPITAL   (United Arab Emirates)

^h Damascus Hospital   (Syrian Arab Republic)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

Adherence; disease modifying drugs; injection devices; middle east; multiple sclerosis

Indexed keywords

BETA1A INTERFERON;

DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRONICS; FREEZE DRYING; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; REVIEW; SELF INJECTION;

ADJUVANTS, IMMUNOLOGIC; DISABLED PERSONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MIDDLE EAST; MULTIPLE SCLEROSIS; NEEDLES; PATIENT COMPLIANCE; SELF ADMINISTRATION;

EID: 79951872415     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.541572     Document Type: Review

References (29)

1. Al-Sabbagh, A., Bennett, R., Kozma, C., Dickson, M., & Meletiche, D. (2008). Medication gaps in disease-modifying drug therapy for multiple sclerosis are associated with an increased risk of relapse: Findings from a national managed care database. 18th meeting of the ENS, Monday 9 June, Poster 321.
2. Atkinson, M. J., Sinha, A., Hass, S. L., Colman, S. S., Kumar, R. N., Brod, M., et al. (2004). Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes, 2, 12.
3. Brochet, B., Lemaire, G., & Beddiaf, A. (2006). Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices. Revue Neurologique (Paris), 162, 735-740. (Pubitemid 44046655)
4. Clanet, M., Kappos, L., Hartung, H. P., & Hohlfeld, R. (2004). Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Multiple Sclerosis, 10, 139-144. (Pubitemid 38499904)
5. Cohen, B. A. (2006). Adherence to disease-modifying therapy for multiple sclerosis. International Journal of Multiple Sclerosis Care, (Suppl), 32-37.
6. Cohen, B. A., & Rieckmann, P. (2007). Emerging oral therapies for multiple sclerosis. International Journal of Clinical Practice, 61, 1922-1930. (Pubitemid 47573097)
7. Conlin, P. R., Gerth, W. C., Fox, J., Roehm, J. B., & Boccuzzi, S. J. (2001). Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clinical Therapeutics, 23, 1999-2010. (Pubitemid 34073191)
8. Cox, D., & Stone, J. (2006).Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. The Journal of Neuroscience Nursing, 38, 167-171.
9. Cramer, J. A., Cuffel, B. J., Divan, V., Al-Sabbagh, A., & Glassman, M. (2006). Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurologica Scandinavica, 113, 156-162.
10. Dahlgren, J. (2008). Easypod: A new electronic injection device for growth hormone. Expert Review of Medical Devices, 5, 297-304.
11. Devonshire, V., Lapierre, Y., Macdonell, R., Ramo-Tello, C., Patti, F., Fontoura, P., et al. (2010). The Global Adherence Project (GAP): A multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology, Vol 10, DOI: 10.1111/j.1468-1331.2010.03110.x.
12. Devonshire, V., Verdun, E., on behalf of the RebiSmart™ User Trial study group. (2009). Delivery technology for multiple sclerosis therapy: An international, multicentre, single-arm, open-label, 12-week, Phase IIIb trial of a new electronic device for subcutaneous injection of interferon beta-1a. 19th Meeting of the European Neurological Society (ENS), Milan, Italy, 20-24 June, Poster 698.
13. Dupclay, L., Jr., & Doyle, J. (2002). Assessment of intranasal corticosteroid use in allergic rhinitis: Benefits, costs, and patient preferences. American Journal of Managed Care, 8, S335-S340.
14. Giovannoni, G., Barbarash, O., Casset-Semanaz, F., King, J., Metz, L., Pardo, G., et al. (2009). Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis, 15, 219-228.
15. IFNB MS Study group. (1995). Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology, 45, 1277-1285.
16. Jaber, A., Bozzato, G. B., Vedrine, L., Prais, W. A., Berube, J., & Laurent, P. E. (2008). A novel needle for subcutaneous injection of interferon beta-1a: Effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurology, 8, 38.
17. Kappos, L., Traboulsee, A., Constantinescu, C., Eralinna, J. P., Forrestal, F., Jongen, P., et al. (2006). Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, 67, 944-953. (Pubitemid 44454583)
18. Lugaresi, A., Durastanti, V., Gasperini, C., Lai, M., Pozzilli, C., Orefice, G., et al. (2008). Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: The CoSa study. Clinical Neuropharmacology, 31, 167-172. (Pubitemid 351787112)
19. Mikol, D., Lopez-Bresnahan, M., Taraskiewicz, S., Chang, P., & Rangnow, J. (2005). A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Multiple Sclerosis, 11, 585-591. (Pubitemid 41387705)
20. Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23, 125-132. (Pubitemid 32488430)
21. O'Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns. Multiple Sclerosis, 11, 46-50. (Pubitemid 40259974)
22. Partridge, A. H., Avorn, J., Wang, P. S., & Winer, E. P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652-661. (Pubitemid 34552485)
23. Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11, 306-309. (Pubitemid 40775187)
24. Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005). Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care, 43, 521-530. (Pubitemid 40847288)
25. Stone, V. E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865-872.
26. Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology, 61, 551-554. (Pubitemid 37025380)
27. Williams, M., Clarke, T., Williams, P., & Barton, E. N. (2007). The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. West Indian Medical Journal, 56, 270-274. (Pubitemid 350200074)
28. World Health Organization. (2003). Adherence to long-term therapies. Evidence for action. WHO. www.iMED.orgiMED.org accessed 14/09/10.
29. Yamout, B. I., Dahdaleh, M., Al Jumah, M. A., Al-Shammri, S., Al Sharoqi, I., Al-Tahan, A. R., et al. (2010). Adherence to disease-modifying drugs in patients with multiple sclerosis: A consensus statement from the Middle East MS Advisory Group. International Journal of Neuroscience, 120, 273-279.